Video

Dr. Ryan on the Long Term Safety of Abiraterone Use

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

The safety profile of abiraterone did not change much in subsequent analyses of COU-AA-302, Ryan says. The main adverse events associated with the agent were related to fluid retention, though there was potential for hypokalemia and liver dysfunction.

It was previously demonstrated that adverse events associated with corticosteroid use can be of concern in patients who remain on abiraterone. However, Ryan says, significant corticosteroid toxicities, such as osteoporotic fractures, were not any worse than what would be seen in the general population of patients.

<<<

View more from the 2015 GU Cancer Symposium

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Louis Crain Garrot, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Bradley C. Carthon, MD, PhD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center